YOLFTbeta
Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV

LKFT · NASDAQ · Healthcare / Biotechnology

33.98USD+0.05 (+0.15%)

Price History

Full chart

Market Stats

Previous Close33.93
Open33.72
Day Range33.22 – 34.14
52-Week Range25.68 – 37.78
Volume287.84K
Market Cap1.92B
P/E (TTM)2.86
Forward P/E344.83
EPS10.26
Dividend Yield0.00%
Beta0.12
50-Day Avg28.27
200-Day Avg30.21

About

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Henry O. Gosebruch
  • Employees196
  • HeadquartersSchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800, USA
  • Websitehttps://lakefrontbio.com

Leadership

  • Mr. Henry O. GosebruchCEO & Executive Director · b. 1973
  • Mr. Aaron L. CoxChief Financial Officer · b. 1984
  • Ms. Christina Carlson J.D.Chief Operating Officer
  • Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
  • Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
  • Marieke VermeerschHead of Corporate Communication
  • Ms. Tania PhilippChief People Officer · b. 1972
  • Ms. Ellen Van Der AarHead of Development
  • Dr. Jeevan ShettyHead of Clinical Development Oncology
  • Ruiz AstigarragaHead of Manufacturing Cell Therapy

Financials

Income Statement

Currency: EUR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue234.38M241.25M239.72M275.65M1.11B
Growth (%)-+2.93%-0.63%+14.99%+303.50%
Cost of Revenue320.50M0034.86M29.74M
Gross Profit-86.12M241.25M239.72M240.79M1.08B
Gross Margin-36.74%100.00%100.00%87.35%97.33%
Operating Expense85.45M372.31M327.99M429.12M581.12M
Operating Income-171.57M-131.06M-88.26M-188.34M501.39M
Operating Margin-73.20%-54.32%-36.82%-68.33%45.08%
EBITDA-163.25M3.87M51.04M43.33M358.96M
EBITDA Margin-69.65%1.60%21.29%15.72%32.27%
Net Income-103.23M-217.99M211.70M74.08M320.88M
Net Income Margin-44.04%-90.36%88.31%26.88%28.85%
R&D320.50M269.80M241.29M335.46M459.42M
R&D as % of Total Revenue136.74%111.83%100.65%121.70%41.31%
Interest Expense8.73M9.15M1.77M911.00K2.22M
Interest Expense % of Total Revenue3.72%3.79%0.74%0.33%0.20%

Balance Sheet

Currency: EUR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-4.73B4.36B4.14B3.41B
Total Liabilities-2.21B1.56B1.24B170.65M
Total Equity-2.53B2.80B2.90B3.24B
Cash-508.12M166.80M64.24M87.87M
Total Debt----6.92M
Net Debt-----80.95M

Cash Flow

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-500.54M-405.97M-320.03M-257.46M
Investing Cash Flow---288.81M
Financing Cash Flow-1.49M-5.00M-4.92M-3.27M
Capital Expenditure36.95M19.27M82.11M13.86M
Free Cash Flow-537.49M-425.24M-402.14M-271.31M
FCF to OCF107.38%104.75%125.66%105.38%

Earnings

Report DateAug 6, 2015Nov 13, 2015Mar 4, 2016Apr 28, 2016Jul 28, 2016Oct 27, 2016Mar 23, 2017Apr 28, 2017Jul 27, 2017Oct 27, 2017Feb 23, 2018Apr 25, 2018Aug 3, 2018Oct 25, 2018Feb 22, 2019Apr 25, 2019Jul 25, 2019Oct 24, 2019Mar 27, 2020May 8, 2020Aug 6, 2020Nov 5, 2020Feb 18, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 23, 2022May 6, 2022Aug 4, 2022Nov 3, 2022Feb 24, 2023May 4, 2023Aug 3, 2023Nov 2, 2023May 2, 2024Aug 1, 2024Oct 30, 2024Feb 13, 2025Apr 23, 2025Jul 23, 2025Nov 5, 2025Mar 26, 2026May 7, 2026Aug 10, 2026
EPS Estimate-0.31--1.18-0.18-0.600.20-0.61-0.71-0.78--0.91-0.84-1.00--1.09-0.962.47-0.72--0.93-0.85-0.81-0.96-1.00-1.23-1.14--0.22-1.24--0.39-0.37-0.85-0.13-0.02-0.12--0.18-0.13-0.28-0.07-0.97-11.50
EPS Actual-0.36-0.78-1.600.79-0.05-0.520.97-0.29-0.74-0.72-0.69-0.73-0.420.280.31-0.89-0.878.13-1.39-0.86-1.75-1.45-0.84-0.23-0.99-0.980.57-0.23-0.29-0.54-3.210.350.080.390.360.07-0.740.410.97-0.93-0.1812.270.210.03
Surprise-16.13%---33.05%72.22%13.33%385.00%52.46%-4.23%7.69%-19.78%50.00%128.00%-18.35%9.38%229.15%-93.06%--88.17%-70.59%-3.70%76.04%1.00%20.33%150.00%--31.82%56.45%-189.74%121.62%145.88%376.92%450.00%-516.67%-638.89%-615.38%35.71%17628.57%121.65%100.26%
TimingPre-market--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hours

Key Statistics & Ratios

Market Cap1.92B
Enterprise Value-581.24M
Trailing P/E2.86
Forward P/E344.83
Price / Sales1.94
Price / Book0.53
EPS10.26
Book Value2.87
Revenue (TTM)990.57M
Gross Profit (TTM)669.75M
EBITDA568.92M
Profit Margin60.23%
Operating Margin-359.30%
Return on Equity20.12%
Return on Assets9.93%
Shares Outstanding65.48M
Shares Float474.38M
Beta0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
23.63%
Insiders
25.45%
Retail / Other
50.92%

Top Institutional Holders

  • TANG CAPITAL MANAGEMENT LLC
    3.79M5.78%
  • Madison Avenue Partners, LP
    2.47M3.76%
  • Prosight Management, LP
    2.04M3.12%
  • EcoR1 Capital, LLC
    1.67M2.55%
  • Ameriprise Financial Inc
    1.42M2.18%
  • Point72 Asset Management, L.P.
    332.13K0.51%
  • Renaissance Technologies Corp
    315.40K0.48%
  • BlackRock Inc
    312.11K0.48%
  • D. E. Shaw & Co LP
    197.84K0.30%
  • Millennium Management LLC
    181.09K0.28%
  • UBS Group AG
    175.29K0.27%
  • Dafna Capital Management LLC
    130.18K0.20%
  • OLD MISSION CAPITAL LLC.
    95.59K0.15%
  • Citadel Advisors Llc
    88.34K0.13%
  • Two Sigma Investments LLC
    81.75K0.12%
  • Man Group PLC
    80.21K0.12%

Top Fund Holders

  • Columbia Overseas Value Inst
    595.59K0.91%
  • HBM Healthcare Investments AG Ord
    378.33K0.58%
  • iShares Biotechnology ETF
    308.67K0.47%
  • Columbia VP Overseas Core 3
    280.32K0.43%